STOCK TITAN

CFTZV Financials

CFTZV
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows CFTZV (CFTZV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CFTZV FY2025

An asset-heavy, debt-funded model keeps operating cash flow positive, but depreciation and interest keep the assets from earning their keep.

Over the past five years, revenue nearly tripled and operating cash flow stayed positive, yet losses persisted because depreciation and interest reached roughly $65.5M in FY2025. That mix explains why reported profit looks weak even though cash arrives: the business throws off cash before the full cost of carrying a very large asset base shows up in earnings, which points to a capital-intensive structure rather than a simple demand problem.

Leverage has become the main constraint: liabilities reached $966.8M in FY2025 while assets were broadly steady, so more of the business is financed by creditors than by retained owner capital. Cash of $25.4M sat below annual interest of $28.3M, making the cash balance look more like operating float than a large reserve.

Capital returns continued despite losses, and shares outstanding fell by roughly a quarter over the last couple of years. At the same time, equity dropped to $170.0M, so each remaining share represented a larger slice of a thinner balance-sheet cushion, which can tidy per-share optics without reducing dependence on borrowed capital.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating CFTZV's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial
5/6

CFTZV passes 5 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
-3.25x

For every $1 of reported earnings, CFTZV generates $-3.25 in operating cash flow ($27.4M OCF vs -$8.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$97.9M
YoY+2.4%
5Y CAGR+44.2%

CFTZV generated $97.9M in revenue in fiscal year 2025. This represents an increase of 2.4% from the prior year.

EBITDA
N/A
Net Income
-$8.4M
YoY+7.9%

CFTZV reported -$8.4M in net income in fiscal year 2025. This represents an increase of 7.9% from the prior year.

EPS (Diluted)
$-0.70
YoY-6.1%

CFTZV earned $-0.70 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 6.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$25.4M
YoY-29.7%
5Y CAGR-5.4%

CFTZV held $25.4M in cash against $600.7M in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
11M
YoY-11.9%

CFTZV had 11M shares outstanding in fiscal year 2025. This represents a decrease of 11.9% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
-8.6%
YoY+1.0pp
5Y CAGR-19.8pp

CFTZV's net profit margin was -8.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.0 percentage points from the prior year.

Return on Equity
-5.0%
YoY-0.9pp
5Y CAGR-6.2pp

CFTZV's ROE was -5.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.9 percentage points from the prior year.

Capital Allocation

R&D Spending
N/A
Share Buybacks
$40.4M
YoY-32.3%
5Y CAGR+54.8%

CFTZV spent $40.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 32.3% from the prior year.

Capital Expenditures
N/A

CFTZV Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $26.6M+7.2% $24.8M+1.5% $24.4M-2.2% $25.0M+5.4% $23.7M+2.2% $23.2M-1.2% $23.4M-9.1% $25.8M
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $991K+306.5% $244K-25.7% $328K+340.4% $75K+0.7% $74K-32.0% $109K+60.4% $68K+7.3% $63K
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense $6.8M-0.9% $6.9M-5.7% $7.3M+2.1% $7.2M+3.7% $6.9M-0.7% $7.0M-2.0% $7.1M+5.0% $6.8M
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$2.5M+50.3% -$5.1M-326.4% -$1.2M+31.1% -$1.7M-283.5% -$449K+90.6% -$4.8M-104.5% -$2.3M-19.1% -$2.0M
EPS (Diluted) $-0.22 N/A $-0.10+28.6% $-0.14-250.0% $-0.04 N/A $-0.17-21.4% $-0.14

CFTZV Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $1.1B-1.2% $1.1B-1.2% $1.2B-0.8% $1.2B-0.2% $1.2B+3.2% $1.1B-1.9% $1.1B+3.0% $1.1B
Current Assets N/A N/A N/A N/A N/A N/A N/A N/A
Cash & Equivalents $23.5M-7.5% $25.4M-14.5% $29.7M+4.2% $28.5M+22.4% $23.3M-35.6% $36.1M+29.3% $27.9M+9.7% $25.5M
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $968.1M+0.1% $966.8M+0.6% $961.3M+0.7% $955.0M+0.9% $946.5M+5.2% $899.5M-1.1% $909.8M+6.2% $856.4M
Current Liabilities N/A N/A N/A N/A N/A N/A N/A N/A
Long-Term Debt $602.6M+0.3% $600.7M-1.8% $611.7M+1.7% $601.7M+2.3% $588.2M N/A N/A N/A
Total Equity $154.7M-9.0% $170.0M-10.3% $189.5M-7.5% $204.9M-5.1% $215.8M-4.7% $226.5M-4.8% $238.0M-7.6% $257.7M
Retained Earnings -$147.3M-3.7% -$142.0M-6.7% -$133.1M-4.5% -$127.3M-5.3% -$120.9M-4.5% -$115.7M-9.2% -$105.9M-7.6% -$98.4M

CFTZV Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$6.0M-202.8% $5.8M+5.3% $5.5M-24.1% $7.3M-15.5% $8.7M-5.8% $9.2M+29.6% $7.1M-23.4% $9.2M
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow $890K+300.0% -$445K+73.6% -$1.7M+31.1% -$2.4M+61.4% -$6.3M-136.5% $17.4M+1310.4% -$1.4M-126.2% $5.5M
Financing Cash Flow $3.1M+132.0% -$9.6M-66.1% -$5.8M-4479.8% $132K+100.9% -$14.1M+22.2% -$18.1M-348.0% -$4.1M+76.6% -$17.3M
Dividends Paid $1.9M-40.1% $3.2M-4.3% $3.3M-1.8% $3.4M+0.5% $3.4M-5.1% $3.5M-4.6% $3.7M-6.4% $4.0M
Share Buybacks $11.2M-2.7% $11.5M-5.4% $12.1M+61.7% $7.5M-19.1% $9.3M-29.9% $13.2M-9.7% $14.6M-6.2% $15.6M

CFTZV Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin -9.5%+10.9pp -20.4%-15.5pp -4.9%+2.0pp -6.9%-5.0pp -1.9%+18.7pp -20.6%-10.6pp -9.9%-2.4pp -7.6%
Return on Equity -1.6%+1.3pp -3.0%-2.3pp -0.6%+0.2pp -0.8%-0.6pp -0.2%+1.9pp -2.1%-1.1pp -1.0%-0.2pp -0.8%
Return on Assets -0.2%+0.2pp -0.4%-0.3pp -0.1%+0.1pp -0.1%-0.1pp -0.0%+0.4pp -0.4%-0.2pp -0.2%-0.0pp -0.2%
Current Ratio N/A N/A N/A N/A N/A N/A N/A N/A
Debt-to-Equity 3.89+0.4 3.53+0.3 3.23+0.3 2.94+0.2 2.73-1.2 3.97+0.1 3.82+0.5 3.32
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Frequently Asked Questions

CFTZV (CFTZV) reported $97.9M in total revenue for fiscal year 2025. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

CFTZV (CFTZV) revenue grew by 2.4% year-over-year, from $95.5M to $97.9M in fiscal year 2025.

No, CFTZV (CFTZV) reported a net income of -$8.4M in fiscal year 2025, with a net profit margin of -8.6%.

CFTZV (CFTZV) reported diluted earnings per share of $-0.70 for fiscal year 2025. This represents a -6.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, CFTZV (CFTZV) had $25.4M in cash and equivalents against $600.7M in long-term debt.

CFTZV (CFTZV) had a net profit margin of -8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

CFTZV (CFTZV) has a return on equity of -5.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

CFTZV (CFTZV) generated $27.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

CFTZV (CFTZV) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

Yes, CFTZV (CFTZV) spent $40.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

CFTZV (CFTZV) had 11M shares outstanding as of fiscal year 2025.

CFTZV (CFTZV) had a debt-to-equity ratio of 3.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

CFTZV (CFTZV) had a return on assets of -0.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

CFTZV (CFTZV) has a Piotroski F-Score of 5 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

CFTZV (CFTZV) has an earnings quality ratio of -3.25x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top